(Q52862339)

9 May 2018

title

Design of an individualized fixed-dose clinical trial to test the antiepileptic efficacy of a plasma flunarizine concentration (English)

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

24 October 2022

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

24 October 2022

2

D. M. Treiman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1665118

24 October 2022

1

G. W. Pledger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1665118

24 October 2022

language of work or name

English

0 references

publication date

1 December 1991

1 reference

9 May 2018

full work available at URL

https://api.elsevier.com/content/article/PII:019724569190040S?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

https://api.elsevier.com/content/article/PII:019724569190040S?httpAccept=text/plain

24 October 2022

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Contemporary Clinical Trials

24 October 2022

published in

1 reference

9 May 2018

volume

12

1 reference

9 May 2018

issue

6

1 reference

9 May 2018

page(s)

768-779

1 reference

9 May 2018

Effects of some anti-epileptic, neuroleptic and gabaminergic drugs on convulsions induced by D,L-allyglycine

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Behavioral analysis of the effects of 15 anticonvulsants in the amygdaloid kindled rat

24 October 2022

2

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Behavioral analysis of amygdaloid kindling in beagle dogs and the effects of clonazepam, diazepam, phenobarbital, diphenylhydantoin, and flunarizine on seizure manifestation

24 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Double-blind placebo-controlled trial of flunarizine as add-on therapy in epilepsy

24 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Double-blind placebo-controlled trial with flunarizine in therapy-resistant epileptic patients.

24 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Flunarizine as a supplementary medication in refractory childhood epilepsy: a double-blind crossover study

24 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Double-blind placebo-controlled evaluation of flunarizine as adjunct therapy in epilepsy with complex partial seizures

24 October 2022

10

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

A controlled study of progabide in partial seizures: methodology and results

24 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Felbamate for partial seizures: results of a controlled clinical trial

24 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Pharmacokinetic profile of flunarizine after single and multiple dosing in epileptic patients receiving comedication

24 October 2022

15

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three-year study in ambulant patients with generalized epileptic seizures

24 October 2022

18

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Single drug therapy for intractable epilepsy

24 October 2022

19

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Sodium Valproate, Serum Level and Clinical Effect in Epilepsy: A Controlled Study

24 October 2022

20

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Phenobarbital treatment of status epilepticus in a rodent model

24 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Lorazepam treatment of experimental status epilepticus in the rat: relevance to clinical practice.

24 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

The randomized concentration-controlled trial: An evaluation of its sample size efficiency

24 October 2022

23

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

24 October 2022

Level off

26

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project

24 October 2022

28

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Bio-behavioral effects of compliance

24 October 2022

29

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

A behavioral medicine perspective on adherence to long-term medical regimens

24 October 2022

30

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates

24 October 2022

31

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

Oral antibiotic prophylaxis in patients with cancer: A double-blind randomized placebo-controlled trial

24 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/0197-2456(91)90040-S

24 October 2022

Identifiers

1 reference

9 May 2018

1 reference

9 May 2018